Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients ...

Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...

Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than ...

Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...

Nobody has ever contracted HIV or hepatitis from toilet roll, as the viruses don't survive for long outside the body.

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company wi ...

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...

he says he's dedicated to participating in new drug studies that can help doctors better understand the disease and treatment options. "As long-term survivors of HIV/AIDS, we still don't know how ...

In particular, lenacapavir which is administered via a twice-yearly injection, represents a dramatic new alternative to the current standard of care for HIV prevention: taking a pill called ...